RT Journal Article
SR Electronic
T1 Characterization of Tumor Immune Microenvironment in Meningiomas: Correlation of Tumor-infiltrating Lymphocyte Aggregates With Tumor Grade
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3487
OP 3496
DO 10.21873/anticanres.17710
VO 45
IS 8
A1 INOMO, TOSHIAKI
A1 OHNO, MASASUKE
A1 NAGASAKA, TORU
A1 KURAMITSU, SHUNICHIRO
A1 ITO, EIJI
A1 WATANABE, TADASHI
A1 FUJITA, MITSUGU
YR 2025
UL http://ar.iiarjournals.org/content/45/8/3487.abstract
AB Background/Aim: Malignant meningiomas are aggressive intracranial tumors with high recurrence rates and limited treatment options. The tumor immune microenvironment (TIME) plays a pivotal role in the tumor progression and treatment response. However, its role in meningioma remains largely unknown. This study aimed to analyze tumor-infiltrating lymphocytes (TILs) within the meningioma TIME and investigate their correlation with clinical parameters.Patients and Methods: Using tumor specimens from patients diagnosed with meningioma (grade 1, 12 cases; grade 2, 10 cases), the densities of CD4+ T-cells, CD8+ T-cells, CD20+ B-cells, and tissue-resident memory T-cells were quantified using multicolor immunohistochemistry and the QuPath software. The results were analyzed along with clinical parameters, including tumor grades.Results: The density of individual TIL subsets did not correlate with the tumor grades or patients’ postoperative neurological function. TIL aggregates were observed in grade 2 meningiomas; clusters of abundant B-cells with a few follicular helper T-cells were observed in one case, indicating the presence of immature tertiary lymphoid structures. A positive correlation was observed between the densities of CD4+ and CD8+ T-cells in grade 2 meningiomas but not in grade 1.Conclusion: The TIME in meningiomas exhibits distinct immune profiles by tumor grade, characterized by the presence of TIL aggregates and coordinated CD4+ and CD8+ T-cell infiltration in higher-grade tumors. These findings may provide insights into the immune landscape of meningiomas and support the development of immunotherapeutic strategies targeting the TIME.